Key Record Dates
ClinicalTrials.gov Identifier: | NCT04209205 |
---|---|
Brief Title: | Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2) |
First Submitted : | October 30, 2019 |
First Submitted that Met QC Criteria : | December 19, 2019 |
First Posted : | December 24, 2019 |
Last Update Submitted that Met QC Criteria : | December 2, 2021 |
Last Update Posted : | December 3, 2021 |